主要研究兴趣：

1. NK细胞与肿瘤免疫微环境；

2. 肿瘤免疫干预靶点的寻找与药物研发。

中国科学技术大学生命科学与医学部 特任教授，博士生导师，国家基金委优青获得者（2021），安徽省杰青获得者（2021）。2009本科毕业于安徽医科大学，2015年博士毕业于中国科学技术大学免疫学研究所，2015年至2018年期间在中国科学技术大学生命科学学院工作，先后任博士后和副研究员，2021年转为特任教授。主要从事NK细胞与肿瘤免疫研究，相关成果以通讯作者和第一作者发表在Nat Immunol、Cancer Res、Clinic Cancer Res、Nati Sci Rev和Cell Mol Immunol等学术期刊，获中国科学院院长优秀奖（2015）和中国免疫学会青年学者奖（2021）。

代表性研究论文：

[1] Zhigang Nian, Xiaohu Zheng*, Yingchao Dou, Xianghui Du, Li Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Haiming Wei*, Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells, Clinic Cancer Research, 2021, DOI: 10.1158/1078-0432. (IF=12.703)

[2] Jiacheng Bi, Chaoyue Zheng and Xiaohu Zheng*. Increased expression of adenosine A3 receptor in tumor-infiltrating natural killer cells. Cell Mol Immunol. 2021, DOI: 10.1038/s41423-020-00632-1. (IF=11.531)

[3] Xiaohu Zheng, Haiming Wei*. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. 2021, Front Oncol, DOI: 10.3389/fonc.2021.628243. (IF=6.242)

[4] Yonggang Zhou^#; Binqing Fu^#; Xiaohu Zheng^#; Dongsheng Wang; Changcheng Zhao; Yingjie qi; Rui Sun; Zhigang Tian; Xiaoling Xu*; Haiming Wei*. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review. 2020, DOI:10.1093/nsr/nwaa041. (IF=17.275)

[5] Xin Zhang, Dong Wang, Zhidong Li, Defeng Jiao, Linlin Jin, Jingjing Cong, Xiaohu Zheng* and Lijun Xu*. Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Front Immunol, Feb 2020, Volume 11. (IF=7.562)

[6] Xiaohu Zheng, Yeben Qian, Binqing Fu, Defeng Jiao, Yong Jiang, Peng Chen, Yiqing Shen, Huafeng Zhang, Rui Sun, Zhigang Tian* and Haiming Wei *, Mitochondrial fragmentation limits natural killer cell-based tumour immunosurveillance. Nature Immunology, 2019 Dec, 20;1656-1667. (IF=25.6)

[7] Yong Jiang^#, Xiaohu Zheng^#, Defeng Jiao, Peng Chen, Yechuan Xu, Haiming Wei*, Yeben Qian*. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine, 2019 Feb;40:422-431. (IF=8.141)

[8] Xiaohu Zheng , Fan X, Fu B, Zheng M, Zhang A, Zhong K, Yan J, Sun R, Tian Z*, Wei H*, EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance. Cancer Research, JAN 15 2017, 77; 482-493. (IF=12.703)

[9] Xiaohu Zheng, Min Cheng, Binqing Fu, Xiaolei Fan, Qing Wang, Xiaoqing Yu, Rui Sun, Zhigang Tian*, Haiming Wei*.Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Research, March 15, 2015 75; 1080-90. (IF=12.533)

[10] Xiaohu Zheng, Zhigang Tian, Haiming Wei*. Lung specific X protein as a novel therapeutic target for lung cancer. OncoImmunology, 2015 Aug 17;4(12):e1052931. (IF=8.114)

招生招聘：

1. 实验室招聘具有免疫学、细胞生物学等相关背景的博士后或特任副研究员；

2. 实验室欢迎对肿瘤、免疫学感兴趣的学生前来攻读硕士或博士学位。

 联系方式：ustczxh@ustc.edu.cn